STAAR Surgical Company (STAA)
NASDAQ: STAA · Real-Time Price · USD
30.29
-0.40 (-1.30%)
At close: Oct 29, 2024, 4:00 PM
30.68
+0.39 (1.29%)
After-hours: Oct 29, 2024, 4:59 PM EDT

Company Description

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.

The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.

It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.

The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.

STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

STAAR Surgical Company
STAAR Surgical Company logo
Country United States
Founded 1982
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 1,057
CEO Thomas Frinzi

Contact Details

Address:
25651 Atlantic Ocean Drive
Lake Forest, California 92630
United States
Phone 626 303 7902
Website staar.com

Stock Details

Ticker Symbol STAA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000718937
CUSIP Number 852312305
ISIN Number US8523123052
Employer ID 95-3797439
SIC Code 3851

Key Executives

Name Position
Thomas G. Frinzi President, Chief Executive Officer and Chairman
Patrick F. Williams Chief Financial Officer
Warren Foust Chief Operating Officer
Dr. Keith Holliday Ph.D. Chief Technology Officer
Dr. Scott D. Barnes M.D. Chief Medical Officer
Brian Moore Vice President of Investor Relations and Corporate Development
Nathaniel B. Sisitsky Esq. General Counsel and Corporate Secretary
Nancy Sabin Chief Marketing Officer
James Francese Senior Vice President of Commercial Operations - North America and APAC
Dr. Magda Michna Ph.D. Chief Clinical, Regulatory and Medical Affairs Officer

Latest SEC Filings

Date Type Title
Oct 18, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 6, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 7, 2024 10-Q Quarterly Report
Aug 7, 2024 8-K Current Report
Jun 21, 2024 S-8 Securities to be offered to employees in employee benefit plans
Jun 21, 2024 8-K Current Report
Jun 12, 2024 8-K Current Report
May 7, 2024 10-Q Quarterly Report
May 7, 2024 8-K Current Report
Apr 24, 2024 ARS Filing